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CONCLUSION(S)
The Amikacin loaded nanolipsomes were successfully formulated with characteristics similar to 
Arikayce® with particle size range of less than 300nm.
FUTURE WORK
The future optimization of Ethanol injection method (formulation and process parameters), in vitro, 
and preclinical in vivo testing are needed to test the developed Amk-NLs. 
ANDERSEN CASCADE IMPACTOR STUDY
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RATIONALE, HYPOTHESIS AND AIM
Mycobaterium avium complex (MAC) lung disease is a serious condition, that in some 
cases can cause severe, even permanent damage to the lungs1. Amikacin is a 
polycationic, semisynthetic, bactericidal aminoglyocoside. The entry of the moiety is 
mediated by binding of the antibacterial moiety to the negatively charged components 
of the bacterial cell wall. The primary mechanism of action involves the disruption and 
inhibition of protein synthesis in the target bacteria by binding to the 30S ribosomomal
subunit. Arikayce® approved by FDA in 2018 and generic of Arikayce® is not available at 
the moment. Due to the complex NLs dosage form, the development of generics takes a 
longer time compared to the conventional dosage form. The aim is to develop and 
characterize the Amikacin (Amk) loaded extended release nanoliposomes (NLs) by 
ethanol injection method.
Central Hypothesis:- Inhaled Amk-NLs will produce a robust and consistent quality 





• Prepare 20mL 0.9%w/v solution of Sodium Chloride and add 50 mg Amikacin 
to it to form 1.10mg/ml drug concentration of final formulation. Let it 
dissolve completely at 50°C.
Preparation 
of  Lipid 
phase
• Prepare 1.3mL 90%V/V ethanolic solution. Add 17.29mg DPPC and 8.65mg 
Cholesterol.
• Stir well for the lipids to completely dissolve in the ethanolic solution giving 




• Using a syringe pump, the ethanolic lipid solution was injected into 0.9%w/v 
Sodium Chloride solution containing drug at 50°C at a flow rate of 
0.15mL/min, while continuously stirring at 600 rpm.
• Stir the solution continuously at 600 rpm for 30 min after the injection is 
completed, maintaining the temperature.
Extrusion 
from a Avanti 
mini extruder • Using an avanti mini extruder, the formulation was passed through a 0.1µm 
membrane to achieve particle size of less than 250 nm.
Parameter Value
Particle size 386 ± 25 nm 
Polydispersity 
Index
0.32 ± 0.03 
Zeta Potential 1.08 ± 0.95 mV 
% Entrapment 58.32 ± 2.1 %
TABLE 1: Parameter for amikacin 
inhalational NL before extrusion 
process (mean ± SD, n=3)
Parameter Value
Particle size 215.26 ± 0.49  nm 
Polydispersity Index 0.43 ± 0.02 
Zeta Potential 0.08 ± 0.015 mV 
% Entrapment 63.45 ± 1.1 %
TABLE 2: Parameter for amikacin 
inhalational NL after extrusion process 
(mean ± SD, n=3)
RESULTS
Figure 3: Andersen Cascade Impactor Study.
Each of the plates of the impactor was coated with 
Tween 80 to prevent bouncing of particles during 
nebulization and were thereafter weighed. A filter 
paper was placed on the last collector stage
A compressor nebulizer, Sami the 
Seal (Philips Respironics, NJ) was 
operated at a flow rate of 
28.3+0.5 L/min as recommended 
by United States 
Pharmacopeia(USP) and the 
formulation was nebulized for 10 
minutes.
After nebulization, the impactor was 
dissembled and all the plates were 
again weighed. The mass median 
aerodynamic diameter (MMAD), 
geometric standard deviation (GSD) 
of the formulation were calculated 


























































































Effective Cut off diameter (nm)
8 stage non-viable Anderson cascade impactor (Westech Scientific Instruments Marietta, GA) was used to determine the aerodynamic particle size 
distribution of the formulation. 













































Graph 1: Particle Size variation for 21 days
Graph 2: Polydispersity Index variation for 21 days
Graph 3: Zeta Potential variation for 21 days
The MMAD and GSD for the Amikacin were found to be 4.13±0.134 um and 1.82±0.064 respectively.
The particle size  data signifies that the 
formulation maintained its particle size 
range for a period of 21 days indicating 
that Amikacin loaded NL’s were stable.
The polydispersity index  data signifies 
that the formulation maintained its 
particle size range for a period of 21 days 
indicating no agglomeration meaning that 
Amikacin loaded NL’s were stable.
The zeta potential  data signifies that the formulation 
maintained its charge range for a period of 21 days 
indicating that Amikacin loaded NL’s were stable.
The % fine particle fraction after the experiment was found to be 42.01± 6.901.
